Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
(St. Jude Reference #)
|Chimeric Receptors with 4-1BB Stimulatory Signaling Domain (SJ-03-0018A)|
|Description||A targeted immunotherapy that utilizes a patented anti-CD19 CAR to genetically modify human immune cells (US 8,399,645). This CAR stimulates immune cells to destroy the most common forms of adult and childhood B cell cancers including acute lymphoblastic leukemia (ALL), B-cell chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin lymphoma (NHL). Each year approximately 71,650 people in the United States are diagnosed with these diseases.|
|Keywords||anti-CD19 Chimeric Antigen Receptor, CAR, leukemia therapy|
|Granted Patents or Published Applications||U.S. Patent No. 8,399,645|
|Related Scientific References||A press release issued by St. Jude is available here: http://www.stjude.org/immune-cells-patent|
|Licensing Opportunities||We are currently entertaining offers to license this technology from a number of companies. If your company would like to be included in this process, please contact us as soon as possible for more information.|
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.
Last update: August 2013